XPHYF News and Press, XPhyto Therapeutics Corp From 06/30/21

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significa...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberr...

XPhyto signs master supply agreement with operator of 10 COVID-19 test centers The test will be offered to customers as a rapid PCR test with sample processing on site Commercial operations expected to commence upon delivery of kits VANCOUVER, BC / ACCESSWIRE / June 30, 2021 ...

The majority of individuals who contract the coronavirus suffer from the symptoms of coughing, fever and difficulty breathing before recovering in about two weeks. However, some individuals suffer persistent symptoms , informally referred to as long COVID. Researchers estimate that these in...

For many states with legal cannabis markets, one of the objectives of legalizing the controversial drug was to cripple the illicit cannabis market by taking away its clientele. While that sounds like a great idea in theory, most of these states have been unable to do any real damage to the...

As psychedelics have become more popular and research has found the numerous benefits these substances potentially hold, microdosing has increased in popularity as well. For those who may not have come across the term, it refers to the practice of consuming low doses of psychedelic subst...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A rece...

New research conducted by researchers from the University of California-Santa Cruz has found that an individual dose of tabernanthalog (“TBG”) can repair neural circuits in the brain that are damaged by stress, enhance neuronal connection regrowth and remedy behavioral defi...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a life sciences technology accelerator, was featured in the Bell2Bell Podcast , a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndicatio...

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell P...